[Thromboembolic Risk and Prophylaxis in Hospitalized Surgical and Internal Medicine Patients. German Results of the International ENDORSE Study]
Overview
Authors
Affiliations
Background And Objectives: Venous thromboembolism (VTE) leads to an increased morbidity in hospitalized patients. This multinational cross-sectional survey was designed to assess the prevalence of VTE risk factors and to determine the proportion of at-risk patients who receive effective VTE-prophylaxis. The results of the 16 participating German hospitals of the study are presented and compared with the international results.
Patients And Methods: All hospital inpatients aged >or= 40 years admitted to a medical ward and all surgical inpatients aged >or= 18 years were enrolled. The American College of Chest Physicians (ACCP) guidelines (2004) were applied to assess VTE risk and to determine whether patients were receiving recommended VTE prophylaxis.
Results: Overall, 2,370 patients were enrolled: 1,210 (51 %) were categorised as surgical and 1,160 (49 %) as acute medically ill. 838 (69 %) of surgical and 479 (41 %) of medical patients were judged to be at risk for VTE. Of the surgical patients at risk, 772 (92 %) received ACCP-recommended VTE prophylaxis, compared with 337 (70 %) medical patients at risk of VTE. Low-molecular weight heparins were most frequently used.
Conclusions: In total, in comparison to other countries, Germany has a leading position in the implementation of international guidelines with regard to VTE prophylaxis. Whereas in a surgical ward effective VTE prophylaxis is consistently standard care, in the medical indications there is still room for improvement in terms of stratification of VTE risk and corresponding VTE-prophylaxis.
Direct Oral Anticoagulants and Travel-related Venous Thromboembolism.
Chamnanchanunt S, Rojnuckarin P Open Med (Wars). 2018; 13:575-582.
PMID: 30519635 PMC: 6272050. DOI: 10.1515/med-2018-0085.
Chandrakumar A, Sajid A, Suriyaprakash T, Ajmal K Indian Heart J. 2016; 68(4):513-8.
PMID: 27543474 PMC: 4990734. DOI: 10.1016/j.ihj.2015.12.003.
Schellong S, Kaiser J, Bramlage P J Thromb Thrombolysis. 2014; 39(2):173-8.
PMID: 24996649 DOI: 10.1007/s11239-014-1095-0.
Use of rivaroxaban in Germany: a database drug utilization study of a drug started in hospital.
Jobski K, Enders D, Amann U, Suzart K, Wallander M, Schink T Eur J Clin Pharmacol. 2014; 70(8):975-81.
PMID: 24858823 PMC: 4088992. DOI: 10.1007/s00228-014-1697-7.
Pinjala R Indian J Med Res. 2012; 136(1):60-7.
PMID: 22885265 PMC: 3461719.